Literature DB >> 1221141

Studies on the active principles of magnolia bark. Centrally acting muscle relaxant activity of magnolol and hōnokiol.

K Watanabe, H Y Watanabe, Y Goto, N Yamamoto, M Yoshizaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1221141     DOI： 10.1254/jjp.25.605

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN： 0021-5198


× No keyword cloud information.
  9 in total

1.  Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, exerts antiepileptic effects via the GABA/benzodiazepine receptor complex in mice.

Authors:  C R Chen; R Tan; W M Qu; Z Wu; Y Wang; Y Urade; Z L Huang
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

2.  Honokiol inhibits bladder cancer cell invasion through repressing SRC-3 expression and epithelial-mesenchymal transition.

Authors:  Lan Shen; Fang Zhang; Ruimin Huang; Jun Yan; Bing Shen
Journal:  Oncol Lett       Date:  2017-07-25       Impact factor: 2.967

Review 3.  PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.

Authors:  Taemin Oh; Michael E Ivan; Matthew Z Sun; Michael Safaee; Shayan Fakurnejad; Aaron J Clark; Eli T Sayegh; Orin Bloch; Andrew T Parsa
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

4.  Improved Pharmaceutical Properties of Honokiol via Salification with Meglumine: an Exception to Oft-quoted ∆pKa Rule.

Authors:  Xiaoshuang He; Yuanfeng Wei; Shiru Wang; Jianjun Zhang; Yuan Gao; Shuai Qian; Zunting Pang; Weili Heng
Journal:  Pharm Res       Date:  2022-07-14       Impact factor: 4.580

5.  Anti-inflammatory and analgesic effects of magnolol.

Authors:  J P Wang; M F Hsu; S L Raung; C C Chen; J S Kuo; C M Teng
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-12       Impact factor: 3.000

Review 6.  Honokiol, a multifunctional antiangiogenic and antitumor agent.

Authors:  Levi E Fried; Jack L Arbiser
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

7.  The inhibitory effect of magnolol on cutaneous permeability in mice is probably mediated by a nonselective vascular hyporeactivity to mediators.

Authors:  J P Wang; S L Raung; C C Chen; J S Kuo; C M Teng
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

8.  Effector mechanism of magnolol-induced apoptosis in human lung squamous carcinoma CH27 cells.

Authors:  Shu-Er Yang; Ming-Tsuen Hsieh; Tung-Hu Tsai; Shih-Lan Hsu
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

9.  Cardiovascular protection of magnolol: cell-type specificity and dose-related effects.

Authors:  Jennifer Hui-Chun Ho; Chuang-Ye Hong
Journal:  J Biomed Sci       Date:  2012-07-31       Impact factor: 8.410
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.